Literature DB >> 26770415

Correlation analysis of urine metabolites and clinical staging in patients with ovarian cancer.

Ting Jiang1, Yunliang Lin1, Haiqin Yin2, Shanshan Wang1, Qinglei Sun1, Peihai Zhang3, Wenxiang Bi4.   

Abstract

This study is to investigate the correlation between urine metabolites and clinical staging in patients with ovarian cancer. The urina sanguinis from 56 cases of primary epithelial ovarian cancer patients and 15 healthy volunteers was collected and the urine metabolites were extracted. Ultra high performance liquid chromatography/time-of-flight mass spectrometry (UPLC-Q-TOF-MS) analysis was performed. Principal component analysis (PCA) and partial least squares discriminant analysis (PLS-DA) were used to analyze the mass spectrometry data. Database retrieval and comparison of the screened metabolites were performed and one-way ANOVA and least significant difference (LSD) t test were carried out. PCA analysis of UPLC-Q-TOF-MS results showed that the score plots of samples from healthy people and patients with ovarian cancer at different clinical stages were separated. Further PLS-DA analysis significantly improved the classification results. The R(2)X was 0.757, the R(2)Y was 0.977 and the Q(2)Y was 0.87, indicating that the model stability and predictability were good. Eight metabolites, including N-acetylneuraminic acid-9-phosphate, 5'-methioadenosine, uric acid-3-nucleoside, pseudouridine, L-valine, succinic acid, L-proline and β-nicotinamide mononucleotide were identified. The contents of these metabolites increased with the development of the disease. There was correlation between urine metabolites and clinical staging in patients with ovarian cancer.

Entities:  

Keywords:  Ovarian cancer; metabonomics; staging; ultra high performance liquid chromatography/time-of-flight mass spectrometry; urine

Year:  2015        PMID: 26770415      PMCID: PMC4694315     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  23 in total

Review 1.  Recurrent epithelial ovarian cancer: an update on treatment.

Authors:  Olivia W Foley; J Alejandro Rauh-Hain; Marcela G del Carmen
Journal:  Oncology (Williston Park)       Date:  2013-04       Impact factor: 2.990

2.  Metabonomics study of liver cancer based on ultra performance liquid chromatography coupled to mass spectrometry with HILIC and RPLC separations.

Authors:  Jing Chen; Wenzhao Wang; Shen Lv; Peiyuan Yin; Xinjie Zhao; Xin Lu; Fengxia Zhang; Guowang Xu
Journal:  Anal Chim Acta       Date:  2009-04-01       Impact factor: 6.558

3.  Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling.

Authors:  Tao Zhang; Xiaoyan Wu; Chaofu Ke; Mingzhu Yin; Zhenzi Li; Lijun Fan; Wang Zhang; Haiyu Zhang; Falin Zhao; Xiaohua Zhou; Ge Lou; Kang Li
Journal:  J Proteome Res       Date:  2012-12-03       Impact factor: 4.466

4.  Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids.

Authors:  Y J Xiao ; B Schwartz; M Washington; A Kennedy; K Webster; J Belinson; Y Xu
Journal:  Anal Biochem       Date:  2001-03       Impact factor: 3.365

5.  Urinary metabonomic study on colorectal cancer.

Authors:  Yunping Qiu; Guoxiang Cai; Mingming Su; Tianlu Chen; Yumin Liu; Ye Xu; Yan Ni; Aihua Zhao; Sanjun Cai; Lisa X Xu; Wei Jia
Journal:  J Proteome Res       Date:  2010-03-05       Impact factor: 4.466

6.  Urinary hydrophilic and hydrophobic metabolic profiling based on liquid chromatography-mass spectrometry methods: Differential metabolite discovery specific to ovarian cancer.

Authors:  Jing Chen; Lina Zhou; Xiaoyan Zhang; Xin Lu; Rui Cao; Congjian Xu; Guowang Xu
Journal:  Electrophoresis       Date:  2012-10-27       Impact factor: 3.535

Review 7.  In 2014, can we do better than CA125 in the early detection of ovarian cancer?

Authors:  Joshua G Cohen; Matthew White; Ana Cruz; Robin Farias-Eisner
Journal:  World J Biol Chem       Date:  2014-08-26

8.  Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer.

Authors:  Miranda Y Fong; Jonathan McDunn; Sham S Kakar
Journal:  PLoS One       Date:  2011-05-19       Impact factor: 3.240

9.  Metabolomic profile of hepatitis C virus-infected hepatocytes.

Authors:  Barbara Roe; Elizabeth Kensicki; Robert Mohney; William W Hall
Journal:  PLoS One       Date:  2011-08-11       Impact factor: 3.240

10.  A metabolomic approach to identifying platinum resistance in ovarian cancer.

Authors:  Laila M Poisson; Adnan Munkarah; Hala Madi; Indrani Datta; Sharon Hensley-Alford; Calvin Tebbe; Thomas Buekers; Shailendra Giri; Ramandeep Rattan
Journal:  J Ovarian Res       Date:  2015-03-26       Impact factor: 4.234

View more
  7 in total

Review 1.  Pseudouridine as a novel biomarker in prostate cancer.

Authors:  Jennifer A Stockert; Rachel Weil; Kamlesh K Yadav; Natasha Kyprianou; Ashutosh K Tewari
Journal:  Urol Oncol       Date:  2020-07-22       Impact factor: 3.498

Review 2.  Nuclear magnetic resonance spectroscopy as a new approach for improvement of early diagnosis and risk stratification of prostate cancer.

Authors:  Bo Yang; Guo-Qiang Liao; Xiao-Fei Wen; Wei-Hua Chen; Sheng Cheng; Jens-Uwe Stolzenburg; Roman Ganzer; Jochen Neuhaus
Journal:  J Zhejiang Univ Sci B       Date:  2017 Nov.       Impact factor: 3.066

3.  Usefulness of Amino Acid Profiling in Ovarian Cancer Screening with Special Emphasis on Their Role in Cancerogenesis.

Authors:  Szymon Plewa; Agnieszka Horała; Paweł Dereziński; Agnieszka Klupczynska; Ewa Nowak-Markwitz; Jan Matysiak; Zenon J Kokot
Journal:  Int J Mol Sci       Date:  2017-12-16       Impact factor: 5.923

4.  A characteristic biosignature for discrimination of gastric cancer from healthy population by high throughput GC-MS analysis.

Authors:  Yinan Chen; Jun Zhang; Lei Guo; Lei Liu; Jingran Wen; Lu Xu; Min Yan; Zuofeng Li; Xiaoyan Zhang; Peng Nan; Jinling Jiang; Jun Ji; Jianian Zhang; Wei Cai; Huisheng Zhuang; Yan Wang; Zhenggang Zhu; Yingyan Yu
Journal:  Oncotarget       Date:  2016-12-27

5.  Serum Metabolomic Analysis of Feline Mammary Carcinomas based on LC-MS and MRM Techniques.

Authors:  Jia-San Zheng; Ren-Yue Wei; Zheng Wang; Jun Song; Yan-Song Ge; Rui Wu
Journal:  J Vet Res       Date:  2020-11-06       Impact factor: 1.744

Review 6.  The role of m6A, m5C and Ψ RNA modifications in cancer: Novel therapeutic opportunities.

Authors:  Paz Nombela; Borja Miguel-López; Sandra Blanco
Journal:  Mol Cancer       Date:  2021-01-18       Impact factor: 27.401

7.  Complex metabolic interactions between ovary, plasma, urine, and hair in ovarian cancer.

Authors:  Xiaocui Zhong; Rui Ran; Shanhu Gao; Manlin Shi; Xian Shi; Fei Long; Yanqiu Zhou; Yang Yang; Xianglan Tang; Anping Lin; Wuyang He; Tinghe Yu; Ting-Li Han
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.